U.S. Markets closed
  • S&P 500

    4,704.54
    +15.87 (+0.34%)
     
  • Dow 30

    35,870.95
    -60.10 (-0.17%)
     
  • Nasdaq

    15,993.71
    +72.14 (+0.45%)
     
  • Russell 2000

    2,363.59
    -13.42 (-0.56%)
     
  • Gold

    1,861.20
    -0.20 (-0.01%)
     
  • Silver

    24.88
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1369
    -0.0006 (-0.0568%)
     
  • 10-Yr Bond

    1.5890
    -0.0150 (-0.94%)
     
  • Vix

    17.59
    +0.48 (+2.81%)
     
  • GBP/USD

    1.3497
    -0.0003 (-0.0216%)
     
  • USD/JPY

    114.3040
    +0.0520 (+0.0455%)
     
  • BTC-USD

    54,426.25
    -243.67 (-0.45%)
     
  • CMC Crypto 200

    1,402.14
    -65.80 (-4.48%)
     
  • FTSE 100

    7,255.96
    -35.24 (-0.48%)
     
  • Nikkei 225

    29,683.09
    +84.43 (+0.29%)
     

Purinergic Receptor Antagonists Market Insights 2021 - Players Include Incyte, Arcus Biosciences and Corvus Pharmaceuticals Among Others - ResearchAndMarkets.com

·2 min read

DUBLIN, September 24, 2021--(BUSINESS WIRE)--The "Purinergic Receptor (Purinoceptor) Antagonists - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Purinergic Receptor (Purinoceptor) Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Purinergic Receptor (Purinoceptor) Antagonists R&D. The therapies under development are focused on novel approaches to treat/improve Purinergic Receptor (Purinoceptor) Antagonists.

Purinergic Receptor (Purinoceptor) Antagonists Emerging Drugs Chapters

This segment of the Purinergic Receptor (Purinoceptor) Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Purinergic Receptor (Purinoceptor) Antagonists drugs?

  • How many Purinergic Receptor (Purinoceptor) Antagonists drugs are developed by each company?

  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Purinergic Receptor (Purinoceptor) Antagonists?

  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Purinergic Receptor (Purinoceptor) Antagonists therapeutics?

  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

  • What are the clinical studies going on for Purinergic Receptor (Purinoceptor) Antagonists and their status?

  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Incyte Corporation

  • Arcus Biosciences

  • Corvus Pharmaceuticals

  • Idorsia Pharmaceuticals

  • Tarus Therapeutics

  • Dizal Pharmaceutical

  • Corvus Pharmaceuticals

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/1ex7v0

View source version on businesswire.com: https://www.businesswire.com/news/home/20210924005222/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900